Navigation Links
Biomarker test for Peripartum Cardiomyopathy could help reduce death after giving birth
Date:5/17/2014

Athens, 17 May 2014: Cardiologists have discovered biomarkers that can be used to develop a screening test to detect Peripartum Cardiomyopathy (PPCM), a life-threatening disorder that is the primary cause of mortality in pregnant women in developing countries. The results, which can lead to the immediate treatment of PPCM in new mothers and a significant reduction in mortality, were presented at Heart Failure 2014, which opened the World Congress on Acute Heart Failure in Athens the 17 to the 20 May.

"For pregnant women there are two major causes of death: massive hemorrhage and PPCM, and it is a very sad situation because a time of great happiness turns to great sorrow and the new baby and the father are left alone," said study co-author Professor Alexandre Mebazaa, from the Hopital Lariboisiere, Paris. "Here we have found a way to detect rather quickly whether the woman has PPCM and to treat it quickly and efficiently."

PPCM is the leading cause of death in women who are pregnant or have just given birth in Haiti, South African and Egypt, according to the study's authors. Treatment was often delayed because it was difficult to know whether the women were experiencing normal symptoms of pregnancy or PPCM. The new discovery will allow doctors to administer a blood test to determine whether the woman has PPCM and begin effective treatment immediately.

"There's an urgent need for biomarkers of PPCM since the condition can be hard to differentiate from the normal symptoms of pregnancy that include dyspnoea, oedema and palpitations", said Professor Karen Sliwa, a co-author from the University of Cape Town, South Africa.

The authors hypothesized that since angiogenesis and relaxin-2 pathways are altered in PPCM the biomarkers ratio of these two pathways placental growth factors/sFlt-1 and relaxin-2 could be used to discriminate PPCM among peripartum women.

In the study, plasma was withdrawn from 77 PPCM patients, 75 healthy peripartum women, 25 breast feeding mothers, and 65 non-pregnant acute heart failure (HF) patients and tested for levels of cardiovascular (NT-proBNP), anti- (sFlt-1) and angiogenic [Placental (PlGF) or vascular endothelial (VEGF)] .

Results showed that compared to the other groups, PPCM patients had significantly higher levels of NT-proBNP, lower levels of plasma relaxin-2, and that the sFlt-1/PlGF ratio and sFlt-1/VEGF ratio were statistically lower.

"The next step will be to confirm our findings in a larger cohort and if they hold we could go on to develop a bed side test similar to NT-pro BNP in HF," said Professor Sliwa.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-622-834-576
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Researchers present findings on promising biomarker for esophageal cancer
2. Microfluidic technology reveals potential biomarker for early pancreatic cancer
3. NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
4. Proteomics International biomarker study closer to a CDx test for diabetic kidney disease
5. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
6. New study looks at biomarkers in assessing pitch counts bearing on injury
7. Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
8. Game changer: Biomarker identified for noncancerous pancreatic cysts
9. Lung and bladder cancers have common cell-cycle biomarkers
10. Brain biomarker shows promise in heart
11. Biomarkers in blood show potential as early detection method of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the top ... Living (SHSL) may not share those same worries thanks to a new bundled ... while holding the line on increasing their contributions, including premiums, deductibles and the portions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: